141 related articles for article (PubMed ID: 10493608)
1. In vitro activity of epiroprim, a dihydrofolate reductase inhibitor, singly and in combination with brodimoprim and dapsone, against Mycobacterium leprae.
Dhople AM
Int J Antimicrob Agents; 1999 Aug; 12(4):319-23. PubMed ID: 10493608
[TBL] [Abstract][Full Text] [Related]
2. In vivo activity of epiroprim, a dihydrofolate reductase inhibitor, singly and in combination with dapsone, against Mycobacterium leprae.
Dhople AM
Int J Antimicrob Agents; 2002 Jan; 19(1):71-4. PubMed ID: 11814771
[TBL] [Abstract][Full Text] [Related]
3. In vitro and in vivo activity of K-130, a dihydrofolate reductase inhibitor, against Mycobacterium leprae.
Dhople AM
Arzneimittelforschung; 1999 Mar; 49(3):267-71. PubMed ID: 10219472
[TBL] [Abstract][Full Text] [Related]
4. Effect of brodimoprim on Mycobacterium leprae in vitro and in mouse foot-pads.
Dhople AM; Ortega I; Seydel JK; Gardner GD
Indian J Lepr; 1990; 62(1):76-86. PubMed ID: 2193064
[TBL] [Abstract][Full Text] [Related]
5. Antimicrobial activities of dihydrofolate reductase inhibitors, used singly or in combination with dapsone, against Mycobacterium ulcerans.
Dhople AM
J Antimicrob Chemother; 2001 Jan; 47(1):93-6. PubMed ID: 11152437
[TBL] [Abstract][Full Text] [Related]
6. In vitro and in vivo experiments with the new inhibitor of mycobacterium leprae brodimoprim alone and in combination with dapsone.
Seydel JK; Wempe EG; Rosenfeld M; Jagannathan R; Mahadevan PR; Dhople AM
Arzneimittelforschung; 1990 Jan; 40(1):69-75. PubMed ID: 2187440
[TBL] [Abstract][Full Text] [Related]
7. Activity of epiroprim (Ro 11-8958), a dihydrofolate reductase inhibitor, alone and in combination with dapsone against Toxoplasma gondii.
Chang HR; Arsenijevic D; Comte R; Polak A; Then RL; Pechère JC
Antimicrob Agents Chemother; 1994 Aug; 38(8):1803-7. PubMed ID: 7986011
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of epiroprim (Ro11-8958), a new dihydrofolate reductase inhibitor, in the treatment of acute Toxoplasma infection in mice.
Martinez A; Allegra CJ; Kovacs JA
Am J Trop Med Hyg; 1996 Mar; 54(3):249-52. PubMed ID: 8600759
[TBL] [Abstract][Full Text] [Related]
9. In vitro and in vivo effects of N-methyl-3,5-dichloro-benzylamine hydrochloride on Mycobacterium leprae.
Dhople AM; Strong LC; Meindl W; Schoenenberger H; Gardner GD
Arzneimittelforschung; 1991 Mar; 41(3):253-6. PubMed ID: 1867663
[TBL] [Abstract][Full Text] [Related]
10. In vitro and in vivo interactions of drugs used in multidrug therapy in leprosy.
Dhople AM; Lamoureux LC; Gardner GD
Indian J Lepr; 1991; 63(2):166-79. PubMed ID: 1664440
[TBL] [Abstract][Full Text] [Related]
11. Measurement of hypoxanthine incorporation in purified suspensions of Mycobacterium leprae: a suitable method to screen for anti-leprosy agents in vitro.
Wheeler PR
J Med Microbiol; 1988 Mar; 25(3):167-74. PubMed ID: 3279214
[TBL] [Abstract][Full Text] [Related]
12. Antibacterial activities of epiroprim, a new dihydrofolate reductase inhibitor, alone and in combination with dapsone.
Locher HH; Schlunegger H; Hartman PG; Angehrn P; Then RL
Antimicrob Agents Chemother; 1996 Jun; 40(6):1376-81. PubMed ID: 8726004
[TBL] [Abstract][Full Text] [Related]
13. Search for newer antileprosy drugs.
Dhople AM
Indian J Lepr; 2000; 72(1):5-20. PubMed ID: 10935183
[TBL] [Abstract][Full Text] [Related]
14. Diaminodiphenylsulfone resistance of Mycobacterium leprae due to mutations in the dihydropteroate synthase gene.
Kai M; Matsuoka M; Nakata N; Maeda S; Gidoh M; Maeda Y; Hashimoto K; Kobayashi K; Kashiwabara Y
FEMS Microbiol Lett; 1999 Aug; 177(2):231-5. PubMed ID: 10474189
[TBL] [Abstract][Full Text] [Related]
15. In-vitro activity of three new fluoroquinolones and synergy with ansamycins against Mycobacterium leprae.
Dhople AM; Ibanez MA
J Antimicrob Chemother; 1993 Sep; 32(3):445-51. PubMed ID: 8262866
[TBL] [Abstract][Full Text] [Related]
16. Combination of PS-15, epiroprim, or pyrimethamine with dapsone in prophylaxis of Toxoplasma gondii and Pneumocystis carinii dual infection in a rat model.
Brun-Pascaud M; Chau F; Garry L; Jacobus D; Derouin F; Girard PM
Antimicrob Agents Chemother; 1996 Sep; 40(9):2067-70. PubMed ID: 8878582
[TBL] [Abstract][Full Text] [Related]
17. In-vitro activity of sitafloxacin (DU-6859a), either singly or in combination with rifampin analogs, against Mycobacterium leprae.
Dhople AM; Namba K
J Infect Chemother; 2003 Mar; 9(1):12-5. PubMed ID: 12673400
[TBL] [Abstract][Full Text] [Related]
18. Dapsone drug resistance in the MDT era.
Roche PW; Neupane KD; Failbus SS; Butlin CR
Int J Lepr Other Mycobact Dis; 2000 Sep; 68(3):323-5. PubMed ID: 11221097
[No Abstract] [Full Text] [Related]
19. In vitro activity of a new rifamycin derivative against Mycobacterium leprae.
Dhople AM; Dimova V
Arzneimittelforschung; 1996 Feb; 46(2):210-2. PubMed ID: 8720317
[TBL] [Abstract][Full Text] [Related]
20. In vitro and in vivo results of brodimoprim and analogues alone and in combination against E. coli and mycobacteria.
Seydel JK
J Chemother; 1993 Dec; 5(6):422-9. PubMed ID: 8195833
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
